OALib Journal期刊

ISSN: 2333-9721

費用:99美元

投稿

時間不限

2020 ( 345 )

2019 ( 729 )

2018 ( 820 )

2017 ( 752 )

自定義范圍…

匹配條件: “A. Channing” ,找到相關結果約462279條。
列表顯示的所有文章,均可免費獲取
第1頁/共462279條
每頁顯示
A new grass frog from Namibia
A. Channing
African Zoology , 2012,
Abstract: ENGLISH ABSTRACT: A new species of grass frog of the genus Ptychadena is described from northern Namibia. Although superficially similar to Ptychadena schillukorum and Ptychadena mossambica, the new species differs in advisement call, and external characters. An examination of a series of published sonagrams indicates that Ptychadena floweri must be regarded as a junior synonym of P. schillukorum. ******* AFRIKAANSE OPSOMMING: 'n Nuwe graspadda-spesies van die genus Ptychadena word van noordelike Namibia beskryf. Alhoewel dit oppervlakkig soortgelyk is aan Ptychadena schillukorum en Ptychadena mossambica, is daar duidelike verskille in advertensieroep en eksterne kenmerke. 'n Ondersoek van 'n reeks sonagramme toon dat Ptychadena floweri 'n junior sinoniem van P. schillukorum is.
Description of a new moss frog from the south-western Cape (Anura: Ranidae: Arthroleptella)
A. Channing,D. Hendricks,A. Dawood
African Zoology , 2012,
Abstract: ENGLISH ABSTRACT: A new species of moss frog, genus Arthroleptella, is described from the Kleinrivier mountains of the south-western Cape. lt is morphologically indistinguishable from the other three species in the area. The four Cape species are allopatric, each has a unique male advertisement call, and preliminary molecular data shows consistent differences. ************* AFRIKAANSE OPSOMMING: 'n Nuwe mospadda-spesie van die genus Arthroleptetla van die Kleinrivierberge word beskryf. Dit is morlologies ononderskeibaar van die ander drie spesies in die gebied. Al vier Kaapse spiesies is allopatriese, elkeen het 'n unieke advertensieroep, en voorlopige molekulêre data toon kenmerkende verskille.
Description of a tetraploid Tomopterna (Anura: Ranidae) from South Africa
A. Channing,J.P. Bogart
African Zoology , 2011,
Abstract: A new tetraploid species of sand frog, genus Tomoptema, is described from the eastern Cape. On the basis of mtDNA sequences, allozymes and advertisement calls, it appears to have arisen as a hybrid between the adjacent diploid populations of T. de/a/andii and T. cryptotis. The hybridization event is estimated to have occurred 1,5 MYA. Excluding Xenopus. this is the only allotetraploid member of an advanced frog family that is known.
Maternal anxiety associated with fetal echocardiography  [PDF]
Alexandra Channing, Katherine Rosenberg, Catherine Monk, Charles S. Kleinman, Julie S. Glickstein, Stephanie M. Levasseur, Lynn L. Simpson, Ismee A. Williams
Open Journal of Pediatrics (OJPed) , 2012, DOI: 10.4236/ojped.2012.22024
Abstract: Background: Women awaiting fetal echocardiography (fECHO) report high anxiety. It is unclear if anxiety decreases after performance of fECHO. Methods: At fECHO, subjects’ current (state) vs baseline (trait) anxiety was assessed using the Spielberger State-Trait Anxiety Inventory. Anxiety scores of the pre- and post-fECHO groups were compared. Results: From January 2007 to January 2009, we recruited 84 subjects: 40 pre-fECHO and 44 post-fECHO. Of the post-fECHO group, 30 had normal fetal cardiac structure and function confirmed, 12 were told of an abnormality, and 2 were told to follow up equivocal results. Anxiety scores were compared between the 40 pre-fECHO subjects and the 30 post-fECHO subjects with normal results. The mean state anxiety score of the pre-fECHO group was higher than that of the post-fECHO group (42.1 ± 15.1 vs 30.8 ± 8.5, p < 0.001); there was no difference in trait scores. Neither state nor trait anxiety was associated with maternal age, parity, history of miscarriage or known fetal anomaly. Compared to those with a normal fECHO (N = 30), subjects with an abnormal fECHO result (N = 12) had higher state anxiety (46.8 ± 15.5 vs 30.8 ± 8.5, p = 0.005). There was no difference in anxiety scores between subjects awaiting fECHO and post-fECHO subjects who had an abnormal result. Conclusion: Immediately following normal fECHO, women report low anxiety compared with women awaiting fECHO. Women awaiting fECHO report anxiety levels that are as high as women who are told there is fetal cardiac anomaly.
Description of the tadpole of Amietia wittei (Anura: Pyxicephalidae) from the highlands of Kenya
Domnick Victor Wasonga,Alan Channing
African Zoology , 2011,
Abstract: The tadpole ofAmietia wittei (Anura: Pyxicephalidae) is described from the highlands of Kenya. It is distinguished from the tadpoles of Amietia ruwenzoriensis and A. angolensis in the region by the numbers of labial tooth rows.
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Channing J Paller, Emmanuel S Antonarakis
Drug Design, Development and Therapy , 2011, DOI: http://dx.doi.org/10.2147/DDDT.S13029
Abstract: bazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer Review (11284) Total Article Views Authors: Channing J Paller, Emmanuel S Antonarakis Published Date March 2011 Volume 2011:5 Pages 117 - 124 DOI: http://dx.doi.org/10.2147/DDDT.S13029 Channing J Paller, Emmanuel S Antonarakis Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA Abstract: Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) approved cabazitaxel as a new option for patients with CRPC whose disease progresses during or after docetaxel treatment. For most of these patients, cabazitaxel will now replace mitoxantrone (a drug that was FDA-approved because of its palliative effects) as the treatment of choice for docetaxel-refractory disease. The approval of cabazitaxel was based primarily on the TROPIC trial, a large (n = 755) randomized Phase III study showing an overall median survival benefit of 2.4 months for men with docetaxel-pretreated metastatic CRPC receiving cabazitaxel (with prednisone) compared to mitoxantrone (with prednisone). Cabazitaxel is a novel tubulin-binding taxane that differs from docetaxel because of its poor affinity for P-glycoprotein (P-gp), an ATP-dependent drug efflux pump. Cancer cells that express P-gp become resistant to taxanes, and the effectiveness of docetaxel can be limited by its high substrate affinity for P-gp. Preclinical and early clinical studies show that cabazitaxel retains activity in docetaxel-resistant tumors, and this was confirmed by the TROPIC study. Common adverse events with cabazitaxel include neutropenia (including febrile neutropenia) and diarrhea, while neuropathy was rarely observed. Thus, the combination of cabazitaxel and prednisone is an important new treatment option for men with docetaxel-refractory metastatic CRPC, but this agent should be administered cautiously and with appropriate monitoring (especially in men at high risk of neutropenic complications).
Corrigendum
Channing J Paller, Emmanuel S Antonarakis
Drug Design, Development and Therapy , 2011, DOI: http://dx.doi.org/10.2147/DDDT.S19759
Abstract: Corrigendum Corrigendum (4118) Total Article Views Authors: Channing J Paller, Emmanuel S Antonarakis Published Date March 2011 Volume 2011:5 Pages 183 - 184 DOI: http://dx.doi.org/10.2147/DDDT.S19759 Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy. 2011;5:117–124. The drug Jevtana was incorrectly named Jentava in Table 4. Original Article Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Other articles by Dr Emmanuel Antonarakis Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer Readers of this article also read: New atypical antipsychotics for schizophrenia: iloperidone Available and emerging treatments for Parkinson’s disease: a review Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer Preliminary study of highly cross-linked hyaluronic acid-based combination therapy for management of knee osteoarthritis-related pain Short communication: carboxylate functionalized superparamagnetic iron oxide nanoparticles (SPION) for the reduction of S. aureus growth post biofilm formation Gene expression profiles in primary duodenal chick cells following transfection with avian influenza virus H5 DNA plasmid encapsulated in silver nanoparticles Facile one-step coating approach to magnetic submicron particles with poly(ethylene glycol) coats and abundant accessible carboxyl groups Cancer stem cell theory: therapeutic implications for nanomedicine Oral biofilms: molecular analysis, challenges, and future prospects in dental diagnostics
Cryptic species of sharp-nosed reed frogs in the Hyperolius nasutus complex: advertisement call differences
Alan Channing,David Moyer,Marius Burger
African Zoology , 2011,
Abstract: The sharp-nosed reed frog is widespread in Africa. Although currently recognized as one species, suggestions have been made that more than one species might exist. We analysed 237 calls of 69 males from 19 localities in the western to southern parts of Africa. Calls fall into three groups, which we recognize as cryptic species. Of eight published sound spectrograms, all can be assigned to one of the three species. We recognize Hyperolius nasutus, distributed from western Africa to the Okavango Delta in Botswana; Hyperolius viridis, from the central highlands of northwestern Zambia to southern Tanzania; and Hyperolius acuticeps which occurs from the Ivory Coast to the southeastern coast of South Africa. We assign published names to the synonymies of these three species. No call data are available for populations in the Congo basin.
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Channing J Paller,Emmanuel S Antonarakis
Drug Design, Development and Therapy , 2011,
Abstract: Channing J Paller, Emmanuel S AntonarakisSidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USAAbstract: Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) approved cabazitaxel as a new option for patients with CRPC whose disease progresses during or after docetaxel treatment. For most of these patients, cabazitaxel will now replace mitoxantrone (a drug that was FDA-approved because of its palliative effects) as the treatment of choice for docetaxel-refractory disease. The approval of cabazitaxel was based primarily on the TROPIC trial, a large (n = 755) randomized Phase III study showing an overall median survival benefit of 2.4 months for men with docetaxel-pretreated metastatic CRPC receiving cabazitaxel (with prednisone) compared to mitoxantrone (with prednisone). Cabazitaxel is a novel tubulin-binding taxane that differs from docetaxel because of its poor affinity for P-glycoprotein (P-gp), an ATP-dependent drug efflux pump. Cancer cells that express P-gp become resistant to taxanes, and the effectiveness of docetaxel can be limited by its high substrate affinity for P-gp. Preclinical and early clinical studies show that cabazitaxel retains activity in docetaxel-resistant tumors, and this was confirmed by the TROPIC study. Common adverse events with cabazitaxel include neutropenia (including febrile neutropenia) and diarrhea, while neuropathy was rarely observed. Thus, the combination of cabazitaxel and prednisone is an important new treatment option for men with docetaxel-refractory metastatic CRPC, but this agent should be administered cautiously and with appropriate monitoring (especially in men at high risk of neutropenic complications).Keywords: cabazitaxel, castration-resistant prostate cancer, clinical trial, docetaxel resistance, drug development
Corrigendum
Channing J Paller,Emmanuel S Antonarakis
Drug Design, Development and Therapy , 2011,
Abstract: Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.Drug Design, Development and Therapy. 2011;5:117–124. The drug Jevtana was incorrectly named Jentava in Table 4.Original Article
第1頁/共462279條
每頁顯示


Home
Copyright ? 2008-2017 Open Access Library. All rights reserved.

久草在现在线中文字幕